参考文献/References:
[1]盛凌黎,曹子怡,郭小平,等.加味陈氏糖肾方治疗糖尿病肾脏病G3-4A1-3期合并脂代谢紊乱临床研究[J].陕西中医,2025,46(2):192-196.
[2]夏彦,雷亚军,张楠.糖尿病肾病危险因素的相关性分析[J].保健医学研究与实践,2015,12(1):32-35.
[3]WANG M,PANG Y,GUO Y,et al.Metabolic reprogramming:A novel therapeutic target in diabetic kidney disease[J].Front Pharmacol,2022,13:970601.
[4]PETRENKO V,SINTUREL F,RIEZMAN H,et al.Lipid metabolism around the body clocks[J].Prog Lipid Res,2023,91:101235.
[5]LEI Q,YANG J,LI L,et al.Lipid metabolism and rheumatoid arthritis[J].Front Immunol,2023,14:1190607.
[6]谷梦彤,房城,王旭,等.中药调控脂肪酸代谢重编程干预糖尿病肾病研究进展[J].天津中医药大学学报,2025,44(4):366-372.
[7]DUAN Y,GONG K,XU S,et al.Regulation of cholesterol homeostasis in health and diseases:From mechanisms to targeted therapeutics[J].Signal Transduct Target Ther,2022,7(1):265.
[8]WANG Y,LIU T,WU Y,et al.Lipid homeostasis in diabetic kidney disease[J].Int J Biol Sci,2024,20(10):3710-3724.
[9]JIN H R,WANG J,WANG Z J,et al.Lipid metabolic reprogramming in tumor microenvironment:From mechanisms to therapeutics[J].J Hematol Oncol,2023,16(1):103.
[10]WEI Y,YANG H,ZHOU L,et al.Targeting lipid metabolic reprogramming to alleviate diabetic kidney disease:Molecular insights and therapeutic strategies[J].Front Immunol,2025,16:1549484.
[11]MITROFANOVA A,BURKE G,MERSCHER S,et al.New insights into renal lipid dysmetabolism in diabetic kidney disease[J].World J Diabetes,2021,12(5):524-540.
[12]SU Y,CHEN Q,MA K,et al.Astragaloside Ⅳ inhibits palmitate-mediated oxidative stress and fibrosis in human glomerular mesangial cells via downregulation of CD36 expression[J].Pharmacol Rep,2019,71(2):319-329.
[13]MUKHI D,LI L,LIU H,et al.ACSS2 gene variants determine kidney disease risk by controlling de novo lipogenesis in kidney tubules[J].J Clin Invest,2023,134(4):e172963.
[14]CHENG C,GENG F,LI Z,et al.Ammonia stimulates SCAP/insig dissociation and SREBP-1 activation to promote lipogenesis and tumour growth[J].Nat Metab,2022,4(5):575-588.
[15]LU J,LI X Q,CHEN P P,et al.Activation of acetyl-CoA synthetase 2 mediates kidney injury in diabetic nephropathy[J].JCI Insight,2023,8(20):e165817.
[16]LIU X,DUCASA G M,MALLELA S K,et al.Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and alport syndrome[J].Kidney Int,2020,98(5):1275-1285.
[17]MOHANDES S,DOKE T,HU H,et al.Molecular pathways that drive diabetic kidney disease[J].J Clin Invest,2023,133(4):e165654.
[18]周松兰,杨晓瑞,熊清,等.Nesfatin-1激活PPARγ信号通路调节脂代谢改善大鼠肥胖症实验研究[J].陕西医学杂志,2025,54(6):748-753.
[19]LI Q,ZHAO Y,GUO H,et al.Impaired lipophagy induced-microglial lipid droplets accumulation contributes to the buildup of TREM1 in diabetes-associated cognitive impairment[J].Autophagy,2023,19(10):2639-2656.
[20]AFSHINNIA F,NAIR V,LIN J,et al.Increased lipogenesis and impaired β-oxidation predict type 2 diabetic kidney disease progression in american indians[J].JCI Insight,2019,4(21):e130317.
[21]LIN S,WANG L,JIA Y,et al.Lipin-1 deficiency deteriorates defect of fatty acid β-oxidation and lipid-related kidney damage in diabetic kidney disease[J].Transl Res,2024,266:1-15.
[22]李凡,王杰,崔成姬,等.基于“脾病下流乘肾”探讨糖尿病肾病研究进展[J].陕西中医,2023,44(12):1823-1826.
[23]马昕瑞,杨宇峰,曲超,等.基于“脂毒”假说探讨中医消渴及脂代谢重编程机制研究[J].辽宁中医药大学学报,2022,24(12):180-183.
[24]殷语蔓,俞赟丰,黄湘宁,等.糖尿病肾病氧化应激的“膏浊”病机与证治探讨[J].中国实验方剂学杂志,2026，3（2）:226-234.
[25]刘苏,刘敬顺.余江毅从“膏脂”辨治糖尿病肾病经验[J].上海中医药杂志,2019,53(10):41-43.
[26]石皓月,杨林静,尚菊菊,等.基于“膏脂生邪-浊毒损络”理论探讨糖尿病心肌损伤“代谢记忆”的中医证治规律[J].中国中医基础医学杂志,2025,31(9):1533-1536.
[27]郎昱希颜,蒋春波.从血瘀理论探讨中医药干预铁死亡调控糖尿病肾病[J].国医论坛,2025,40(2):74-78.
[28]武洁,刘旭光,冯晓辞,等.黄芪多糖调控Wnt1信号对糖尿病大鼠糖脂代谢紊乱影响机制研究[J].辽宁中医药大学学报,2024,26(11):43-51.
[29]XIA H,ZHOU B,SUI J,et al.Lycium barbarum polysaccharide regulates the lipid metabolism and alters gut microbiota in high-fat diet induced obese mice[J].Int J Environ Res Public Health,2022,19(19):12093.
[30]RONG Q,HAN B,LI Y,et al.Berberine reduces lipid accumulation by promoting fatty acid oxidation in renal tubular epithelial cells of the diabetic kidney[J].Front Pharmacol,2021,12:729384.
[31]QIAO A,PAN M,ZENG Y,et al.Matrine inhibits high-glucose-diet-induced fat accumulation and Aβ-mediated lipid metabolic disorder via AAK-2/NHR-49 pathway in caenorhabditis elegans[J].Int J Mol Sci,2025,26(7):3048.
[32]WANG J,WANG L,FENG X,et al.Astragaloside Ⅳ attenuates fatty acid-induced renal tubular injury in diabetic kidney disease by inhibiting fatty acid transport protein-2[J].Phytomedicine,2024,134:155991.
[33]JI P,SHI Q,LIU Y,et al.Ginsenoside Rg1 treatment alleviates renal fibrosis by inhibiting the NOX4-MAPK pathway in T2DM mice[J].Ren Fail,2023,45(1):2197075.
[34]YONG W,LI Z,XU W,et al.Quercetin ameliorates renal injury by promoting UCP1-mediated alleviation of lipid accumulation in diabetic kidney disease[J].Phytomedicine,2025,147:157213.
[35]ZHANG Z Z,YV X H,TAN W H.Baicalein inhibits macrophage lipid accumulation and inflammatory response by activating the PPARγ/LXRα pathway[J].Clin Exp Immunol,2022,209(3):316-325.
[36]CHEN Y,TAO J,HE Y,et al.Curcumin targets CXCL16-mediated podocyte injury and lipid accumulation in diabetic kidney disease treatment[J].Arch Pharm Res,2024,47(12):924-939.
[37]GU W,WANG X,ZHAO H,et al.Resveratrol ameliorates diabetic kidney injury by reducing lipotoxicity and modulates expression of components of the junctional adhesion molecule-like/sirtuin 1 lipid metabolism pathway[J].Eur J Pharmacol,2022,918:174776.
[38]SHI G,WU W,WAN Y G,et al.Low dose of triptolide ameliorates podocyte epithelial-mesenchymal transition induced by high dose of D-glucose via inhibiting Wnt3α/β-catenin signaling pathway activation[J].Zhongguo Zhong Yao Za Zhi,2018,43(1):139-146.
[39]ZHANG G,ZHANG H,DONG R,et al.Oleanolic acid attenuates obesity through modulating the lipid metabolism in high-fat diet-fed mice[J].Food Sci Nutr,2024,12(10):8243-8254.
[40]刘宇,胡志娟,邢邯英,等.齐墩果酸对2型糖尿病大鼠肾脏保护作用及机制的研究[J].中国糖尿病杂志,2024,32(3):210-214.
[41]李安,陈云贵,谢高宇,等.基于UHPLC-MS/MS代谢组学探讨金匮肾气丸对慢性肾病肾间质纤维化的改善作用及其机制研究[J].中药药理与临床,2025:1-16.
[42]庞琳蓉,李赛美.黄连温胆汤改善代谢综合征大鼠糖脂代谢的作用及机制研究[J].广州中医药大学学报,2019,36(5):714-718.
[43]SU Z,LI Y,ZHOU Z,et al.Huanglian wendan decoction alleviates metabolic syndrome by reprogramming macrophage polarization:Evidence from multi-omics integration[J].Phytomedicine,2025,146:157119.
相似文献/References:
[1]张华贞.复方黄芪汤加减联合骨化三醇治疗糖尿病肾病疗效及对患者血糖、肾功的影响*[J].陕西中医,2019,(6):767.
[2]程红卫,成晓萍.阎晓萍从脾论治糖尿病肾病经验总结*[J].陕西中医,2019,(6):790.
[3]黄聪丽,王治新△.益气滋肾活血通络方治疗早中期糖尿病肾病临床研究[J].陕西中医,2019,(10):1390.
HUANG Congli,WANG Zhixin..Clinical efficacy analysis of Yiqi Zishen Huoxue Tongluo decoctionon early and medium stage of diabetic nephropathy[J].,2019,(4):1390.
[4]玉山江·艾克木,哈丽达·木沙△,地丽尼嘎尔.西红康联合还原型谷胱甘肽治疗2型糖尿病肾病Ⅲ期气阴两虚夹瘀证疗效及对患者微炎症状态、抗氧化的影响*[J].陕西中医,2020,(3):338.
Yushanjiang·Aikemu,Halida·Musha,Dilinigaer..Efficacy of adjuvant therapy of Xihongkang on type 2 diabetic nephropathy Ⅲ phase with syndrome of Qiyin Liangxu Jiayu type and its effect on micro inflammation and antioxidant role[J].,2020,(4):338.
[5]马民凯,马红建,陈新苗.通络散结汤对3期糖尿病肾病患者GFR、UAER、β2-MG、Cys-C及微炎症状态的影响*[J].陕西中医,2020,(10):1432.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.025]
[6]田娟娟,陈 强,周欣欣,等.益气养阴活血法治疗糖尿病肾病理论探究*[J].陕西中医,2020,(12):1781.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.026]
[7]代广玉,修丽梅.糖尿病肾病中医辨证分型研究进展[J].陕西中医,2021,(1):131.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.036]
[8]赵 亚,张勉之,樊威伟,等.国医大师张大宁治疗糖尿病肾病用药经验[J].陕西中医,2021,(6):773.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.025]
[9]张 蕊,王子承,蒋荣莉,等.防己黄芪汤加味治疗糖尿病肾病疗效及对患者糖脂代谢、氧化应激的影响[J].陕西中医,2021,(8):1049.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.015]
ZHANG Rui,WANG Zicheng,JIANG Rongli,et al.Effect of Fangji Huangqi decoction on diabetic nephropathy and its influence on glucose and lipid metabolism and oxidative stress[J].,2021,(4):1049.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.015]
[10]方锦颖,王一冲,神原优滋(日本),等.基于网络药理学和分子对接探究肾康注射液治疗糖尿病肾病作用机制[J].陕西中医,2021,(12):1798.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.039]